8-K: AnaptysBio Announces Positive Phase 2b Rosnilimab Results and Year-End 2024 Financials

AnaptysBio reports positive Phase 2b results for rosnilimab in rheumatoid arthritis and provides a business update alongside its year-end 2024 financial results, highlighting a strong cash position.

Summary

• AnaptysBio announced positive results from its Phase 2b trial of rosnilimab in rheumatoid arthritis (RA), showcasing the highest-ever reported CDAI LDA response over 6 months.
• Full clinical and translational data for rosnilimab in RA is expected in Q2 2025.
• Top-line Phase 2 data for rosnilimab in ulcerative colitis (UC) has been moved up to Q4 2025.
• Phase 1a trials are ongoing for ANB033 (CD122 antagonist) and will initiate this quarter for ANB101 (BDCA2 modulator).
• AnaptysBio entered an exclusive global license agreement with Vanda Pharmaceuticals for imsidolimab (IL-36R antagonist).
• The company's year-end 2024 cash and investments stand at approximately $420 million, providing a cash runway through year-end 2027.
• GSK reported strong commercial performance for Jemperli ($190 million in Q4 2024 sales) with >100% year-over-year growth.
• Collaboration revenue was $43.1 million and $91.3 million for the three and twelve months ended December 31, 2024, compared to $9.0 million and $17.2 million for the three and twelve months ended December 31, 2023.
• Research and development expenses were $42.6 million and $163.8 million for the three and twelve months ended December 31, 2024, compared to $33.5 million and $132.3 million for the three and twelve months ended December 31, 2023.
• Net loss was $21.8 million and $145.2 million for the three and twelve months ended December 31, 2024, compared to a net loss of $42.2 million and $163.6 million for the three and twelve months ended December 31, 2023.

Sentiment

Score: 8

Explanation: The document presents a positive outlook due to the promising clinical trial results, strong cash position, and strategic partnerships. The advancement of multiple programs and the potential for future revenue streams contribute to a favorable sentiment.

Positives

• Positive Phase 2b results for rosnilimab in RA with impressive efficacy and safety data.
• Strong cash position of approximately $420 million, providing a cash runway through year-end 2027.
• Exclusive global license agreement with Vanda Pharmaceuticals for imsidolimab, generating $15 million upfront.
• Advancement of ANB033 and ANB101 into Phase 1 clinical trials.
• Significant growth in Jemperli sales by GSK, leading to increased royalties for AnaptysBio.

Negatives

• The company reported a net loss of $145.2 million for the year ended December 31, 2024.
• Increased research and development expenses due to the development of rosnilimab, ANB032, ANB033 and ANB101.

Risks

• The success of clinical trials is uncertain, and results may not meet expectations.
• Regulatory approval for product candidates is not guaranteed.
• The company's ability to fund development activities and achieve development goals is subject to risks and uncertainties.
• The company faces risks related to protecting its intellectual property.

Future Outlook

AnaptysBio is focused on advancing its clinical programs, including rosnilimab in RA and UC, and progressing ANB033 and ANB101 through Phase 1 trials. The company anticipates key data readouts in 2025 and 2026 and expects its cash runway to extend through year-end 2027.

Management Comments

• Rosnilimabs positive Phase 2b data in rheumatoid arthritis has revealed impressive safety, tolerability and three-month efficacy data that was sustained and surpasses six-month data from competitor all-active, head-to-head trials.
• In Q2 2025, we will report full clinical and translational data, further validating rosnilimabs transformative potential to restore immune homeostasis, not only in RA but also in other diseases like ulcerative colitis.
• We also are excited to report top-line Phase 2 data for rosnilimab in UC moved up to Q4 2025.
• With approximately $420 million of cash coming into 2025, we are well capitalized through year-end 2027, which does not include the significant potential residual royalties and milestones from our GSK financial collaboration.

Industry Context

AnaptysBio's focus on immunology therapeutics aligns with the growing interest in autoimmune and inflammatory diseases. The positive results for rosnilimab in RA could position it as a competitive treatment option in this space. The licensing agreement with Vanda Pharmaceuticals for imsidolimab reflects a trend of companies focusing on core assets and partnering for others.

Comparison to Industry Standards

• The reported CDAI LDA response of 69% at Week 14 in the rosnilimab trial is being touted as the 'highest-ever reported', suggesting a potential best-in-class profile compared to existing RA treatments like Humira (adalimumab) and Enbrel (etanercept).
• GSK's Jemperli, developed in collaboration with AnaptysBio, is competing with other PD-1 inhibitors like Merck's Keytruda and Bristol-Myers Squibb's Opdivo in the immuno-oncology space.
• The cash runway through 2027 provides AnaptysBio with financial flexibility comparable to other clinical-stage biotech companies of similar size, such as Iovance Biotherapeutics and Legend Biotech.

Stakeholder Impact

• Shareholders may benefit from the positive clinical trial results and strong financial position.
• Employees may experience increased job security and opportunities for advancement.
• Patients may have access to new and effective treatments for autoimmune and inflammatory diseases.
• Collaborative partners like GSK and Vanda Pharmaceuticals may benefit from the advancement of AnaptysBio's programs.

Next Steps

• Report full clinical and translational data for rosnilimab in RA in Q2 2025.
• Release top-line Phase 2 data for rosnilimab in UC in Q4 2025.
• Continue enrollment in the global Phase 2 trial for rosnilimab in UC.
• Advance Phase 1a trials for ANB033 and ANB101.
• GSK to report top-line data from COSTAR Lung Phase 3 trial in H1 2025.
• GSK to report top-line data from AZUR-1 pivotal Phase 2 trial in 2026.

Key Dates